Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $925.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Wells Fargo & Company from $750.00 to $925.00 in a report released on Monday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the stock. Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a research note on Friday, October 30th. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price for the company in a research report on Thursday, October 1st. Evercore upped their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Finally, Bank of America lifted their price target on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Down 4.4%

REGN stock opened at $930.67 on Monday. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The business’s 50-day moving average is $800.69 and its two-hundred day moving average is $741.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. The company has a market cap of $95.82 billion, a price-to-earnings ratio of 20.38, a P/E/G ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same period last year, the firm posted $11.83 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Insider Activity

In other news, Director Christine Poon sold 7,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the transaction, the director directly owned 5,219 shares of the company’s stock, valued at $5,057,680.71. The trade was a 60.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Huda Zoghbi sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 20,789 shares of company stock worth $18,766,698. 6.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in REGN. Orbimed Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $11,358,000. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Contravisory Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $6,327,000. Oxbow Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $323,249,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.